Análisis de la acción Sonoma Pharmaceuticals Inc (SNOA)SNOASonoma Pharmaceuticals Inc

Sonoma Pharmaceuticals, Inc. is a global healthcare company. The Company is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. It offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Sonoma Pharmaceuticals Inc (SNOA) is currently trading at $1.31 with a forward P/E ratio of 46.08, indicating high future earnings expectations despite recent losses. The stock has a current RSI of 43.68, suggesting it is nearing oversold territory, but the year-to-date change of -64.01% raises concerns about its long-term viability. The recent FDA clearance for its Microdacyn product could drive future growth, but the significant net losses, including a net loss of $581,000 in Q4 2026, present a risk that investors should consider before buying.

2 analysts cover SNOA: 2 rate it Buy, 0 Hold and 0 Sell.